Onychomycosis Clinical Trial
Official title:
An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months
This was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5%
topical solution in treating distal subungual onychomycosis (a fungal infection) of the
toenail in children and adolescents (ages 6 to 16 years).
Following confirmation of eligibility, including laboratory evidence of a fungal organism in
the toenail, tavaborole topical solution was applied once daily to all affected toenails for
a 48-week treatment period.
Clinical assessment of the extent of infection and safety assessments were performed
periodically throughout the 48-week treatment period, and again at 52 weeks (4 weeks after
stopping the treatment).
A subgroup of enrolled subjects applied the topical solution to all 10 toenails and a small
area of surrounding skin during the first 28 days. These subjects had blood samples analyzed
to evaluate the pharmacokinetics (how the drug moves in the body) of tavaborole topical
solution in children and adolescents.
This was an open-label study to evaluate the safety, tolerability, and pharmacokinetics of
tavaborole 5% topical solution in treating distal subungual onychomycosis (DSO) of the
toenail in pediatric subjects aged 6 to 16 years and 11 months. An eligible subject had a
target great toenail (TGT) with at least 20% involvement, with a positive potassium hydroxide
(KOH) wet mount and positive fungal culture for T. rubrum or T. mentagrophytes.
Eligible subjects applied tavaborole 5% topical solution, once daily to all affected toenails
(the TGT as well as all other toenails having the clinical characteristics of onychomycosis)
throughout the 48 week treatment period.
Subjects were evaluated at Screening, Baseline (Day 1), and at Weeks 2, 4, 8, 16, 24, 32, 40,
48, and 52. Each evaluation included a clinical assessment of the AEs and local tolerability
evaluation.
Additional procedures were performed as follows:
- Mycology sampling at Screening, Week 24, and Week 52/early termination (ET);
- Clinical disease severity of the TGT at Screening, Week 24, and Week 52/ET;
- Safety laboratory testing at Baseline, Week 24, and Week 52/ET;
In this study, there was a PK subgroup of evaluable subjects aged 12 to 16 years and 11
months studied under maximal use conditions. Subjects in this maximal use subgroup applied
the study drug on all 10 toenails, including up to 2 mm of the surrounding skin, for 28 days.
On Day 15, a predose PK sample was collected to assess steady state trough level. On Day 29,
the study drug application was done at the study site, and PK samples were collected prior to
dosing, as well as 4, 6, 8, and 24 hours postdose on Days 29 to 30.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03098615 -
Study Evaluating the Effect of Jublia on Dermatophytomas
|
Phase 4 | |
Recruiting |
NCT01666002 -
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
|
N/A | |
Completed |
NCT01180491 -
A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis
|
N/A | |
Terminated |
NCT01208168 -
Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Terminated |
NCT01208129 -
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Completed |
NCT00385502 -
A Trial of the Safety and Efficacy of EcoNailâ„¢ in the Treatment of Fungus Infections of the Great Toenail
|
Phase 2 | |
Completed |
NCT00253305 -
Topical Gel Anti-Fungal Agent for Tinea Unguium
|
Phase 2 | |
Not yet recruiting |
NCT05809297 -
Diode Laser and Photodynamic Therapy Vs. Ciclopirox.
|
Phase 4 | |
Completed |
NCT02588599 -
A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis
|
N/A | |
Recruiting |
NCT02436291 -
Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01851590 -
Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01452490 -
Diode Laser Treatment of Onychomycosis
|
N/A | |
Withdrawn |
NCT00938925 -
Effectiveness of Podiatry Care on Onychomycosis (EPOCAON)
|
N/A | |
Recruiting |
NCT00808366 -
Efficacy and Safety of RV4104A Ointment in Onychomycosis
|
N/A | |
Completed |
NCT00768768 -
Iontophoretic Application of Terbinafine Gel to the Large Toe Nail
|
Phase 1 | |
Completed |
NCT00781820 -
Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste
|
Phase 3 | |
Completed |
NCT00777868 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
|
Phase 2 | |
Recruiting |
NCT06074315 -
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis
|
N/A | |
Completed |
NCT01039883 -
A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
|
Phase 1 | |
Suspended |
NCT05491603 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis
|
Phase 2 |